UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 70

Sortiert nach

A novel co-existing ZCCHC8-ROS1 and de-novo MET amplification dual driver in advanced lung adenocarcinoma with a good response to crizotinib

Cancer biology & therapy, 2018-12, Vol.19 (12), p.1097-1101

2018

Volltextzugriff (PDF)

CEP72‐ROS1: A novel ROS1 oncogenic fusion variant in lung adenocarcinoma identified by next‐generation sequencing

Thoracic cancer, 2018-05, Vol.9 (5), p.652-655

2018

Volltextzugriff (PDF)

Clinicopathological features and clinical efficacy of crizotinib in Chinese patients with ROS1 -positive non-small cell lung cancer

Oncology letters, 2019-03, Vol.17 (3), p.3466-3474

2019

Volltextzugriff (PDF)

Association between BIM polymorphism and lung cancer outcomes: a meta-analysis

Cellular and Molecular Biology, 2018-08, Vol.64 (11), p.92-96

2018

Volltextzugriff (PDF)

Concurrent ROS1 gene rearrangement and KRAS mutation in lung adenocarcinoma: A case report and literature review

Thoracic cancer, 2018-01, Vol.9 (1), p.159-163

2018

Volltextzugriff (PDF)

Dual drive coexistence of EML4‐ALK and TPM3‐ROS1 fusion in advanced lung adenocarcinoma

Thoracic cancer, 2018-02, Vol.9 (2), p.324-327

2018

Volltextzugriff (PDF)

Comparison of the c‐MET gene amplification between primary tumor and metastatic lymph nodes in non‐small cell lung cancer

Thoracic cancer, 2017-09, Vol.8 (5), p.417-422

2017

Volltextzugriff (PDF)

Clonally‐related primary ALK rearranged adenocarcinoma and associated metastatic lesions

Thoracic cancer, 2018-07, Vol.9 (7), p.881-884

2018

Volltextzugriff (PDF)

Patients harboring ALK rearrangement adenocarcinoma after acquired resistance to crizotinib and transformation to small-cell lung cancer: a case report

OncoTargets and therapy, 2017-01, Vol.10, p.3187-3192

2017

Volltextzugriff (PDF)

Efficacy of pemetrexed plus platinum doublet chemotherapy as first-line treatment for advanced nonsquamous non-small-cell-lung cancer: a systematic review and meta-analysis

OncoTargets and therapy, 2016-01, Vol.9 (Issue 1), p.1471-1476

2016

Volltextzugriff (PDF)

Lung cancer with concurrent EGFR mutation and ROS1 rearrangement: a case report and review of the literature

OncoTargets and therapy, 2016-01, Vol.9, p.4301-4305

2016

Volltextzugriff (PDF)

Patient harboring a novel PIK3CA point mutation after acquired resistance to crizotinib in an adenocarcinoma with ROS1 rearrangement: A case report and literature review

Thoracic cancer, 2017-11, Vol.8 (6), p.714-719

2017

Volltextzugriff (PDF)

EGFR-RAD51 fusion variant in lung adenocarcinoma and response to erlotinib: A case report

Lung cancer (Amsterdam, Netherlands), 2018-01, Vol.115, p.131-134

2018

Volltextzugriff (PDF)

A novel SOS1-ALK fusion variant in a patient with metastatic lung adenocarcinoma and a remarkable response to crizotinib

Lung cancer (Amsterdam, Netherlands), 2020-04, Vol.142, p.59-62

2020

Volltextzugriff (PDF)

Hepatoid Adenocarcinoma of the Lung with EGFR Mutation and the Response to Tyrosine Kinase Inhibitors

Journal of thoracic oncology, 2019-10, Vol.14 (10), p.e217-e219

2019

Volltextzugriff (PDF)

Hemangioma of the rib: a rare case report and literature review

Open medicine (Warsaw, Poland), 2017-01, Vol.12 (1), p.257-260

2017

Volltextzugriff (PDF)

Ginsenoside compound K inhibits growth of lung cancer cells via HIF-1α-mediated glucose metabolism

Cellular and molecular biology (Noisy-le-Grand, France), 2019-04, Vol.65 (4), p.48

2019

Volltextzugriff (PDF)

A Patient With Lung Adenocarcinoma With BRAF Gene Fusion and Response to Vemurafenib

Clinical lung cancer, 2019-05, Vol.20 (3), p.e224-e228

2019

Volltextzugriff (PDF)

Combined detection of CEA and CA125 for the diagnosis for lung cancer: A meta-analysis

Cellular and Molecular Biology, 2018-12, Vol.64 (15), p.67-70

2018

Volltextzugriff (PDF)

PD-L1 expression level in different thymoma stages and thymic carcinoma: a meta-analysis

Tumori, 2020-08, Vol.106 (4), p.306-311

2020

Volltextzugriff (PDF)

The KIF5B-RET Fusion Gene Mutation as a Novel Mechanism of Acquired EGFR Tyrosine Kinase Inhibitor Resistance in Lung Adenocarcinoma

Clinical lung cancer, 2019-01, Vol.20 (1), p.e73-e76

2019

Volltextzugriff (PDF)

A meta-analysis of association between serum iron levels and lung cancer risk

Cellular and Molecular Biology, 2018-10, Vol.64 (13), p.33-37

2018

Volltextzugriff (PDF)

Lung adenocarcinoma patient with EGFR 19 exon insert mutation and its response to icotinib

Lung cancer (Amsterdam, Netherlands), 2018-07, Vol.121, p.101-104

2018

Volltextzugriff (PDF)

Lung adenocarcinoma patient with an EGFR kinase domain duplication (KDD) and the response to icotinib

Journal of thoracic disease, 2018-05, Vol.10 (5), p.E359-E363

2018

Volltextzugriff (PDF)

A prostate cancer patient with isolated lung metastases: a case report

Translational cancer research, 2020-03, Vol.9 (3), p.2064-2068

2020

Volltextzugriff (PDF)

1 – 25 von 70

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(47)
Mit Volltextzugriff
(67)

Publikationsform

Artikel
(56)
Berichte
(14)

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

A novel co-existing ZCCHC8-ROS1 and de-novo MET amplification dual driver in advanced lung adenocarcinoma with a good response to crizotinib

CEP72‐ROS1: A novel ROS1 oncogenic fusion variant in lung adenocarcinoma identified by next‐generation sequencing

Clinicopathological features and clinical efficacy of crizotinib in Chinese patients with ROS1 -positive non-small cell lung cancer

Association between BIM polymorphism and lung cancer outcomes: a meta-analysis

Concurrent ROS1 gene rearrangement and KRAS mutation in lung adenocarcinoma: A case report and literature review

Dual drive coexistence of EML4‐ALK and TPM3‐ROS1 fusion in advanced lung adenocarcinoma

Comparison of the c‐MET gene amplification between primary tumor and metastatic lymph nodes in non‐small cell lung cancer

Clonally‐related primary ALK rearranged adenocarcinoma and associated metastatic lesions

Patients harboring ALK rearrangement adenocarcinoma after acquired resistance to crizotinib and transformation to small-cell lung cancer: a case report

Efficacy of pemetrexed plus platinum doublet chemotherapy as first-line treatment for advanced nonsquamous non-small-cell-lung cancer: a systematic review and meta-analysis

Lung cancer with concurrent EGFR mutation and ROS1 rearrangement: a case report and review of the literature

Patient harboring a novel PIK3CA point mutation after acquired resistance to crizotinib in an adenocarcinoma with ROS1 rearrangement: A case report and literature review

EGFR-RAD51 fusion variant in lung adenocarcinoma and response to erlotinib: A case report

A novel SOS1-ALK fusion variant in a patient with metastatic lung adenocarcinoma and a remarkable response to crizotinib

Hepatoid Adenocarcinoma of the Lung with EGFR Mutation and the Response to Tyrosine Kinase Inhibitors

Hemangioma of the rib: a rare case report and literature review

Ginsenoside compound K inhibits growth of lung cancer cells via HIF-1α-mediated glucose metabolism

A Patient With Lung Adenocarcinoma With BRAF Gene Fusion and Response to Vemurafenib

Combined detection of CEA and CA125 for the diagnosis for lung cancer: A meta-analysis

PD-L1 expression level in different thymoma stages and thymic carcinoma: a meta-analysis

The KIF5B-RET Fusion Gene Mutation as a Novel Mechanism of Acquired EGFR Tyrosine Kinase Inhibitor Resistance in Lung Adenocarcinoma

A meta-analysis of association between serum iron levels and lung cancer risk

Lung adenocarcinoma patient with EGFR 19 exon insert mutation and its response to icotinib

Lung adenocarcinoma patient with an EGFR kinase domain duplication (KDD) and the response to icotinib

A prostate cancer patient with isolated lung metastases: a case report

Suchergebnisse filtern